An interventional study of Sleepnet Elara Treatment in Sleep Apnea - Obstructive, sponsored by Sleepnet Corporation. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Sleepnet Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 755 studies in Sleep Apnea, Obstructive with a site in United States — 127 open to participants now, 162 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.
Among the 755 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 186th largest by enrollment of the 596 interventional ones that give a count, is one of 42 that started in 2026, is one of 412 with no phase, and was the 732nd registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →127 of the 755 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:
SleepRes Inc. · Sites in United States
Ages 20–80
Pfizer · Sites in United States
Ages 18+
Nevada Dental Sleep · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18–40 · Women only
Fisher and Paykel Healthcare · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
755 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 85 · Phase 3 45 · Phase 4 36
First in 1999; this study’s year is marked. 42 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 52 across 1,476 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 49 across the 596 interventional studies, 81 across the 157 observational. Of the 512 that completed or were terminated, 257 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
193 of 755 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Sleepnet Corporation as lead sponsor.
Sleepnet Corporation has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
67 of the studies in Sleep Apnea, Obstructive with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07613281Serene Sleep, Inc.Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA). | 2026-11 |
| NCT04814420Tulane UniversityAtrial Fibrosis in Obstructive Sleep Apnea Patients: A Pilot Study | 2026-11 |
| NCT07103941Isabel Moreno HayIOA Preventing Occlusal Changes With MAD Use | 2026-11-28 |
Add all 67 to your calendar (.ics) → With an account.
Among the 755 studies in Sleep Apnea, Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the effectiveness of the Elara APAP device.
A prospective open label study to assess the efficacy of the Elara APAP device when used in patients with obstructive sleep apnea. Subjects will sign Informed Consent and undergo screening/baseline and a 1 night in-lab PSG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Sleepnet Elara Treatment
Device: Sleepnet Elara Treatment
Subject to have a 1 night in-lab PSG
AHI 4%
The primary endpoint of this study is treatment night AHI 4%. A subject is considered a success if the Apnea Hypopnea Index calculated by using hypopneas that cause a 4% or greater drop in blood oxygen levels per hour of sleep (AHI4) measured during the 1-night treatment study (PSG) is less than 10 events/hour or less than 10% of the baseline AHI4 value determined at previous diagnosis, whichever is greater.
Time frame: Day 1
Plan to share: No — Not required.
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Oct 2026, 5 months.
Of 118 industry-sponsored interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 5 months is below that.
Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Primary completion moved twice since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, last on Nov 3, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, last on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.